Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03954990 · ClinicalTrials.gov registry record · Phase 1
Treatment of Bacterial Vaginosis Prior to Active Labor and Infectious Morbidity
A Phase 1 study, sponsored by The University of Texas Medical Branch, Galveston.
- Terminated
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
NCT03954990 is a Phase 1 study that was terminated before completion, run by The University of Texas Medical Branch, Galveston. The registered enrollment target is 75 participants.
The verdict
NCT03954990, a Phase 1 study, was terminated before completion, sponsored by The University of Texas Medical Branch, Galveston.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
Study Summary
Bacterial vaginosis (BV) is the most common cause of vaginal discharge among repro-ductive aged women. It is been linked to adverse maternal and neonatal outcomes. Our objective is to evaluate if the use of a single dose of metronidazole in women with BV at time of delivery reduces infectious morbidities
Interventions
- DRUG Placebo Oral Tablet
- DRUG Metronidazole Oral
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2019-10-11 |
| Est. Completion | 2022-09-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03954990
The ClinicalTrials.gov registry entry for NCT03954990 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Medical Branch, Galveston, which has 203 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Oral Tablet is the first listed.
NCT03954990 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03954990 about?
NCT03954990 is a clinical study titled "Treatment of Bacterial Vaginosis Prior to Active Labor and Infectious Morbidity". Bacterial vaginosis (BV) is the most common cause of vaginal discharge among repro-ductive aged women. It is been linked to adverse maternal and neonatal outcomes. Our objective is to evaluate if the use of a single dose of metronidazole in women with BV at time of delivery reduces infectious morbid...
What is the current status of trial NCT03954990?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2019-10-11. Estimated completion is 2022-09-26.
What interventions are being tested in trial NCT03954990?
The interventions under investigation include: Placebo Oral Tablet (DRUG), Metronidazole Oral (DRUG).
Who is sponsoring clinical trial NCT03954990?
This trial is sponsored by The University of Texas Medical Branch, Galveston, which has 203 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.